May. 11 at 2:44 PM
The
$17 million Revance Therapeutics (
$RVNC) deadline is August 28, 2026
If you bought shares between February 29, 2024, and February 6, 2025, you are likely eligible for the
$17 million recovery fund.
This settlement resolves claims that Revance Therapeutics misled investors regarding its Teoxane dispute, delayed Crown tender offer, and related stock-price declines. The stock dropped following the disclosure, and now the company is paying back to impacted shareholders (
$0.16 per share).
File your claim here: https://11th.com/cases/revance-investor-settlement